| Year |
Citation |
Score |
| 2023 |
Wolf MM, Rathmell WK, de Cubas AA. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nature Reviews. Nephrology. PMID 36973495 DOI: 10.1038/s41581-023-00700-5 |
0.301 |
|
| 2022 |
Beebout CJ, Robertson GL, Reinfeld BI, Blee AM, Morales GH, Brannon JR, Chazin WJ, Rathmell WK, Rathmell JC, Gama V, Hadjifrangiskou M. Uropathogenic Escherichia coli subverts mitochondrial metabolism to enable intracellular bacterial pathogenesis in urinary tract infection. Nature Microbiology. 7: 1348-1360. PMID 35995841 DOI: 10.1038/s41564-022-01205-w |
0.735 |
|
| 2022 |
Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. Bmc Cancer. 22: 497. PMID 35513776 DOI: 10.1186/s12885-022-09612-2 |
0.76 |
|
| 2021 |
Reisman BJ, Guo H, Ramsey HE, Wright MT, Reinfeld BI, Ferrell PB, Sulikowski GA, Rathmell WK, Savona MR, Plate L, Rubinstein JL, Bachmann BO. Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. Nature Chemical Biology. PMID 34857958 DOI: 10.1038/s41589-021-00900-9 |
0.751 |
|
| 2021 |
Reinfeld BI, Rathmell WK, Kim TK, Rathmell JC. The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cellular & Molecular Immunology. PMID 34239083 DOI: 10.1038/s41423-021-00727-3 |
0.775 |
|
| 2021 |
Lim AR, Vincent BG, Weaver AM, Rathmell WK. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. Cancer Gene Therapy. PMID 34088993 DOI: 10.1038/s41417-021-00345-1 |
0.625 |
|
| 2021 |
Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. PMID 34019793 DOI: 10.1016/j.cell.2021.04.038 |
0.31 |
|
| 2021 |
Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, ... ... Rathmell WK, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. PMID 33828302 DOI: 10.1038/s41586-021-03442-1 |
0.765 |
|
| 2021 |
Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, ... ... Rathmell WK, et al. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers. 13. PMID 33806963 DOI: 10.3390/cancers13061475 |
0.604 |
|
| 2020 |
Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World Journal of Urology. PMID 32936333 DOI: 10.1007/S00345-020-03441-3 |
0.303 |
|
| 2020 |
Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, Siska PJ, Barone S, Roe CE, Smith CC, Vincent BG, Mason FM, Irish JM, Rathmell WK, Rathmell JC. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. Jci Insight. 5. PMID 32814710 DOI: 10.1172/Jci.Insight.138729 |
0.322 |
|
| 2020 |
Vilgelm AE, Bergdorf K, Wolf M, Bharti V, Shattuck-Brandt R, Blevins A, Jones C, Phifer C, Lee M, Lowe C, Hongo R, Boyd K, Netterville J, Rohde S, Idrees K, ... ... Rathmell WK, et al. Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. Iscience. 23: 101408. PMID 32771978 DOI: 10.1016/J.Isci.2020.101408 |
0.765 |
|
| 2020 |
Bacigalupa ZA, Rathmell WK. Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. Cancer Letters. PMID 32512023 DOI: 10.1016/J.Canlet.2020.05.034 |
0.432 |
|
| 2020 |
de Cubas AA, Dunker W, Zaninovich A, Hongo RA, Bhatia A, Panda A, Beckermann KE, Bhanot G, Ganesan S, Karijolich J, Rathmell WK. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. Jci Insight. 5. PMID 32493845 DOI: 10.1172/Jci.Insight.137569 |
0.415 |
|
| 2020 |
Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 9. PMID 32367803 DOI: 10.7554/Elife.55185 |
0.651 |
|
| 2020 |
Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, et al. Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. Journal of the National Cancer Institute. PMID 32359162 DOI: 10.1093/Jnci/Djaa064 |
0.39 |
|
| 2020 |
Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, ... ... Rathmell WK, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications. 11: 2135. PMID 32358509 DOI: 10.1038/S41467-020-15959-6 |
0.419 |
|
| 2020 |
Raddatz MA, Huffstater TM, Bersi MR, Reinfeld BI, Madden MZ, Booton SE, Rathmell WK, Rathmell JC, Lindman BR, Madhur MS, Merryman WD. Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 (Signal Transducer and Activator of Transcription 3) Splicing. Arteriosclerosis, Thrombosis, and Vascular Biology. ATVBAHA120314360. PMID 32295422 DOI: 10.1161/Atvbaha.120.314360 |
0.732 |
|
| 2020 |
Reinfeld BI, Madden MZ, Ali A, Wolf MM, Young KL, Hongo R, Beckermann KE, Heiden MGV, Muir A, Rathmell JC, Rathmell WK. Abstract 5989: Metabolic heterogeneity of the tumor microenvironment Cancer Research. 80: 5989-5989. DOI: 10.1158/1538-7445.Am2020-5989 |
0.419 |
|
| 2020 |
Battle* D, Rathmell WK, Bergerot C, Msaouel P, Jonasch E, George D, Zhang T, Staehler M. MP14-17 UNDERREPORTING OF SIDE EFFECTS IN SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA The Journal of Urology. 203: e202. DOI: 10.1097/Ju.0000000000000839.017 |
0.348 |
|
| 2019 |
Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK. Correction: loss sensitizes cells to PI3Kβ and AKT inhibition. Oncotarget. 10: 6391-6392. PMID 31695846 DOI: 10.18632/Oncotarget.27288 |
0.592 |
|
| 2019 |
Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet. Oncology. PMID 31427205 DOI: 10.1016/S1470-2045(19)30513-3 |
0.353 |
|
| 2019 |
Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK. loss sensitizes cells to PI3Kβ and AKT inhibition. Oncotarget. 10: 647-659. PMID 30774762 DOI: 10.18632/Oncotarget.26567 |
0.67 |
|
| 2019 |
Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. The Journal of Clinical Investigation. 129: 442-451. PMID 30614813 DOI: 10.1172/Jci120855 |
0.417 |
|
| 2019 |
de Cubas AA, Rathmell WK. Epigenetic modifiers: activities in renal cell carcinoma. Nature Reviews. Urology. 15: 599-614. PMID 30030490 DOI: 10.1038/S41585-018-0052-7 |
0.351 |
|
| 2019 |
Reinfeld BI, Rathmell WK. Untangling ccRCC prognosis with SLINKY. Oncotarget. 8: 18620-18621. PMID 28220033 DOI: 10.18632/Oncotarget.15536 |
0.742 |
|
| 2018 |
Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, ... ... Rathmell WK, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. PMID 30392958 DOI: 10.1016/J.Cell.2018.10.001 |
0.326 |
|
| 2018 |
Rathmell WK, Rathmell JC, Linehan WM. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018792309. PMID 30372395 DOI: 10.1200/Jco.2018.79.2309 |
0.394 |
|
| 2018 |
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, et al. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine. PMID 30291359 DOI: 10.1038/S41591-018-0235-Z |
0.309 |
|
| 2018 |
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, ... ... Rathmell WK, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer. PMID 30287223 DOI: 10.1016/J.Clgc.2018.09.005 |
0.372 |
|
| 2018 |
Smith CC, Beckermann KE, Bortone DS, de Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. The Journal of Clinical Investigation. PMID 30137025 DOI: 10.1172/Jci121476 |
0.445 |
|
| 2018 |
Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, Ganesan S, Bhanot G, Rathmell WK. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. Jci Insight. 3. PMID 30135306 DOI: 10.1172/Jci.Insight.121522 |
0.43 |
|
| 2018 |
Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, ... ... Rathmell WK, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science (New York, N.Y.). 361: 290-295. PMID 30026228 DOI: 10.1126/Science.Aap8411 |
0.43 |
|
| 2018 |
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine. PMID 29867230 DOI: 10.1038/S41591-018-0053-3 |
0.335 |
|
| 2018 |
Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YH, de Cubas AA, Khan A, ... ... Rathmell WK, et al. SETD2 Haploinsufficiency for Microtubule Methylation is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Research. PMID 29724720 DOI: 10.1158/0008-5472.Can-17-3460 |
0.358 |
|
| 2018 |
Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE. High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. The American Journal of Pathology. PMID 29684361 DOI: 10.1016/J.Ajpath.2018.03.010 |
0.341 |
|
| 2018 |
Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017771485. PMID 29641297 DOI: 10.1200/Jco.2017.77.1485 |
0.336 |
|
| 2018 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Rathmell WK, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 313-326.e5. PMID 29617669 DOI: 10.1016/J.Celrep.2018.03.075 |
0.447 |
|
| 2018 |
Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, Rathmell WK, Dayton PA. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics. 8: 141-155. PMID 29290798 DOI: 10.7150/Thno.19658 |
0.37 |
|
| 2017 |
Dronamraju R, Jha DK, Eser U, Adams AT, Dominguez D, Choudhury R, Chiang YC, Rathmell WK, Emanuele MJ, Churchman LS, Strahl BD. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Research. PMID 29294086 DOI: 10.1093/Nar/Gkx1276 |
0.311 |
|
| 2017 |
Jonasch E, Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, ... ... Rathmell WK, et al. HNF1B loss exacerbates the development of chromophobe renal cell carcinomas. Cancer Research. PMID 28807937 DOI: 10.1158/0008-5472.Can-17-0986 |
0.413 |
|
| 2017 |
Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, ... ... Rathmell WK, et al. Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice. 13: 414-421. PMID 28697319 DOI: 10.1200/Jop.2017.020909 |
0.371 |
|
| 2017 |
Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, ... ... Rathmell WK, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. Jci Insight. 2. PMID 28614802 DOI: 10.1172/Jci.Insight.93411 |
0.415 |
|
| 2017 |
Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Oncoimmunology. 6: e1305535. PMID 28507813 DOI: 10.1080/2162402X.2017.1305535 |
0.367 |
|
| 2017 |
Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Scientific Reports. 7: 43356. PMID 28256615 DOI: 10.1038/Srep43356 |
0.345 |
|
| 2017 |
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, ... ... Rathmell WK, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. PMID 28162975 DOI: 10.1016/J.Ccell.2017.01.001 |
0.3 |
|
| 2017 |
Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. Journal For Immunotherapy of Cancer. 5: 1. PMID 28105368 DOI: 10.1186/S40425-016-0206-1 |
0.38 |
|
| 2017 |
Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis. 6: e287. PMID 28092369 DOI: 10.1038/oncsis.2016.89 |
0.309 |
|
| 2017 |
Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. Urologic Oncology. 35: 102-110. PMID 28089416 DOI: 10.1016/J.Urolonc.2016.12.002 |
0.362 |
|
| 2017 |
Terzo E, Chiang J, Rathmell WK. Abstract 3071: Exploring the molecular mechanism underlying SETD2-PI3Kβ synthetic-lethal interaction in renal cell carcinoma (RCC) Cancer Research. 77: 3071-3071. DOI: 10.1158/1538-7445.Am2017-3071 |
0.414 |
|
| 2016 |
Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer. 123: 200-209. PMID 27861752 DOI: 10.1002/Cncr.30314 |
0.417 |
|
| 2016 |
Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, ... ... Rathmell WK, et al. Management and Outcomes of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. Bju International. PMID 27860149 DOI: 10.1111/Bju.13705 |
0.308 |
|
| 2016 |
Kasoji SK, Chang EH, Mullin LB, Chong WK, Rathmell WK, Dayton PA. A Pilot Clinical Study in Characterization of Malignant Renal Cell Carcinoma Subtype with Contrast-Enhanced Ultrasound. Ultrasonic Imaging. PMID 27659687 DOI: 10.1177/0161734616666383 |
0.369 |
|
| 2016 |
De Velasco G, Miao DD, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen E, Choueiri TK. Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups. Cancer Immunology Research. PMID 27538576 DOI: 10.1158/2326-6066.Cir-16-0110 |
0.377 |
|
| 2016 |
Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, Rathmell WK. Structure/Function Analysis of Recurrent Mutations in SETD2 Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and H3K36 Trimethylation. The Journal of Biological Chemistry. PMID 27528607 DOI: 10.1074/Jbc.M116.739375 |
0.319 |
|
| 2016 |
Haake SM, Weyandt JD, Rathmell WK. Insights into the Genetic Basis of the Renal Cell Carcinomas from the Cancer Genome Atlas (TCGA). Molecular Cancer Research : McR. PMID 27330105 DOI: 10.1158/1541-7786.MCR-16-0115 |
0.313 |
|
| 2016 |
Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27220961 DOI: 10.1158/1078-0432.Ccr-15-1673 |
0.381 |
|
| 2016 |
Chism DD, Rathmell WK. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nature Reviews. Nephrology. PMID 27108841 DOI: 10.1038/Nrneph.2016.58 |
0.349 |
|
| 2016 |
Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, et al. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. Cell Metabolism. 23: 649-62. PMID 27076078 DOI: 10.1016/J.Cmet.2016.03.008 |
0.322 |
|
| 2016 |
Brooks SA, Khandani A, Fielding J, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Alternate metabolic programs define regional variation of relevant biological features in renal cell carcinoma progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26787754 DOI: 10.1158/1078-0432.Ccr-15-2115 |
0.424 |
|
| 2016 |
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson A, Lichtenberg T, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, Cubas AAd, Wenz B, Korpershoek E, ... ... Rathmell WK, et al. Abstract 4371: Integrated molecular characterization of pheochromocytoma and paraganglioma including a novel, recurrent and prognostic fusion gene Cancer Research. 76: 4371-4371. DOI: 10.1158/1538-7445.Am2016-4371 |
0.33 |
|
| 2015 |
Fahey CC, Rathmell WK. A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma. Molecular & Cellular Oncology. 2: e979686. PMID 27308442 DOI: 10.4161/23723556.2014.979686 |
0.423 |
|
| 2015 |
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, ... ... Rathmell WK, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology. 35: S276-304. PMID 26590477 DOI: 10.1016/J.Semcancer.2015.09.007 |
0.345 |
|
| 2015 |
Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urologic Oncology. PMID 26546482 DOI: 10.1016/J.Urolonc.2015.09.015 |
0.409 |
|
| 2015 |
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... Rathmell WK, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917 |
0.415 |
|
| 2015 |
Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis. 36: S184-202. PMID 26106137 DOI: 10.1093/Carcin/Bgv036 |
0.363 |
|
| 2015 |
Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacology & Therapeutics. 150: 143-8. PMID 25614331 DOI: 10.1016/J.Pharmthera.2015.01.010 |
0.383 |
|
| 2015 |
Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology. PMID 25600295 DOI: 10.1016/J.Semcancer.2015.01.001 |
0.388 |
|
| 2015 |
Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y. Erratum to Regulation of KLF4 Turnover Reveals an Unexpected Tissue-Specific Role of pVHL in Tumorigenesis [Molecular Cell, 45, (2012), 233-243] Molecular Cell. 60. DOI: 10.1016/J.Molcel.2015.10.005 |
0.314 |
|
| 2014 |
Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, ... ... Rathmell WK, et al. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. Plos One. 9: e116101. PMID 25542006 DOI: 10.1371/Journal.Pone.0116101 |
0.432 |
|
| 2014 |
Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. Bmc Medical Research Methodology. 14: 138. PMID 25532962 DOI: 10.1186/1471-2288-14-138 |
0.374 |
|
| 2014 |
Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. Bmj (Clinical Research Ed.). 349: g4797. PMID 25385470 DOI: 10.1136/Bmj.G4797 |
0.371 |
|
| 2014 |
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, ... ... Rathmell WK, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 26: 319-30. PMID 25155756 DOI: 10.1016/J.Ccr.2014.07.014 |
0.377 |
|
| 2014 |
Rathmell WK, Brooks SA, Parker JS, Nielsen ME. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. European Urology. 66: e92. PMID 25037640 DOI: 10.1016/J.Eururo.2014.07.002 |
0.317 |
|
| 2014 |
Arreola A, Cowey CL, Coloff JL, Rathmell JC, Rathmell WK. HIF1α and HIF2α exert distinct nutrient preferences in renal cells. Plos One. 9: e98705. PMID 24879016 DOI: 10.1371/Journal.Pone.0098705 |
0.427 |
|
| 2014 |
Chism DD, Rathmell WK. Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1721-3. PMID 24634386 DOI: 10.1158/1078-0432.Ccr-14-0056 |
0.377 |
|
| 2014 |
Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. European Urology. 66: 77-84. PMID 24613583 DOI: 10.1016/J.Eururo.2014.02.035 |
0.392 |
|
| 2014 |
Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Research. 24: 241-50. PMID 24158655 DOI: 10.1101/Gr.158253.113 |
0.343 |
|
| 2014 |
Hakimi AA, Jacobsen A, Mano R, Gonen M, Voss MH, Reuter VE, Rathmell WK, Maranchie JK, Appleman LJ, Tamboli P, Signoretti S, Choueiri TK, Russo P, Motzer RJ, Hsieh JJ. MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.877 |
0.38 |
|
| 2013 |
Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK. Racial difference in histologic subtype of renal cell carcinoma. Cancer Medicine. 2: 744-9. PMID 24403240 DOI: 10.1002/Cam4.110 |
0.335 |
|
| 2013 |
Desimone MC, Rathmell WK, Threadgill DW. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. Journal of the National Cancer Institute. 105: 1355-64. PMID 23990666 DOI: 10.1093/Jnci/Djt226 |
0.363 |
|
| 2013 |
Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. Seminars in Oncology. 40: 421-8. PMID 23972705 DOI: 10.1053/J.Seminoncol.2013.05.006 |
0.463 |
|
| 2013 |
Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. The Journal of Biological Chemistry. 288: 26301-10. PMID 23893409 DOI: 10.1074/Jbc.M113.466086 |
0.334 |
|
| 2013 |
Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metabolism. 17: 372-85. PMID 23473032 DOI: 10.1016/J.Cmet.2013.02.002 |
0.405 |
|
| 2013 |
Kapur P, Peña-Llopis S, Christie A, Zhrebker L, PavÃa-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. The Lancet. Oncology. 14: 159-67. PMID 23333114 DOI: 10.1016/S1470-2045(12)70584-3 |
0.4 |
|
| 2013 |
Fahey CC, Hacker KE, Jin J, Davis IJ, Rathmell WK. Abstract B48: Targeting SETD2 knockout cells: A synthetic lethal approach to treating ccRCC Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-B48 |
0.388 |
|
| 2013 |
Fahey CC, Hacker KE, Jin J, Davis IJ, Rathmell WK. Abstract A07: Targeting SETD2 knockout cells: A synthetic lethal approach to treating ccRCC Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-A07 |
0.38 |
|
| 2013 |
Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson G, Chu A, Beroukhim R, Cibulskis K, Signoretti S, Vandin F, Wu HT, Raphael BJ, Verhaak RGW, Tamboli P, ... Rathmell WK, et al. Comprehensivemolecular characterization of clear cell renal cell carcinoma Nature. 499: 43-49. DOI: 10.1038/Nature12222 |
0.39 |
|
| 2012 |
Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Seminars in Nuclear Medicine. 42: 221-30. PMID 22681671 DOI: 10.1053/J.Semnuclmed.2012.02.002 |
0.328 |
|
| 2012 |
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, ... Rathmell WK, et al. State of the science: an update on renal cell carcinoma. Molecular Cancer Research : McR. 10: 859-80. PMID 22638109 DOI: 10.1158/1541-7786.Mcr-12-0117 |
0.436 |
|
| 2012 |
Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Molecular Cell. 45: 233-43. PMID 22284679 DOI: 10.1016/J.Molcel.2011.11.031 |
0.367 |
|
| 2012 |
Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. European Urology. 61: 258-68. PMID 22030119 DOI: 10.1016/J.Eururo.2011.10.007 |
0.422 |
|
| 2012 |
Brannon AR, Haake S, Kurpad R, Udell I, Smith A, Nielsen M, Pruthi R, Wallen E, Woods M, Rathmell WK. 445 META-ANALYSIS OF CLEAR CELL RENAL CELL CARCINOMA GENE EXPRESSION DELINEATES SUBGROUPS Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.512 |
0.384 |
|
| 2012 |
Haake S, Brannon AR, Kurpad R, Udell I, Smith A, Nielsen M, Pruthi R, Wallen E, Woods M, Rathmell WK. 443 CLEAR CELL RENAL CELL CARCINOMA DISPLAYS DIFFERENTIAL GENE EXPRESSION BASED ON GENDER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.510 |
0.381 |
|
| 2011 |
Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Molecular Oncology. 5: 465-74. PMID 21764651 DOI: 10.1016/J.Molonc.2011.06.002 |
0.429 |
|
| 2011 |
Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. European Urology. 60: 622-33. PMID 21741760 DOI: 10.1016/J.Eururo.2011.06.048 |
0.329 |
|
| 2011 |
Rasmussen N, Rathmell WK. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Current Clinical Pharmacology. 6: 199-206. PMID 21470103 DOI: 10.2174/157488411797189389 |
0.364 |
|
| 2011 |
Arreola A, Rathmell WK. Abstract 4276: Characterization of an ex vivo primary multicellular renal cell culture as a potential model system for renal cell carcinoma tumorigenesis Cancer Research. 71: 4276-4276. DOI: 10.1158/1538-7445.Am2011-4276 |
0.372 |
|
| 2010 |
Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, ... Rathmell WK, et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes & Cancer. 1: 152-163. PMID 20871783 DOI: 10.1177/1947601909359929 |
0.381 |
|
| 2010 |
Hacker KE, Rathmell WK. Emerging molecular classification in renal cell carcinoma: implications for drug development. Targeted Oncology. 5: 75-84. PMID 20645016 DOI: 10.1007/S11523-010-0144-7 |
0.387 |
|
| 2010 |
Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us? Current Oncology Reports. 12: 193-201. PMID 20425079 DOI: 10.1007/S11912-010-0093-4 |
0.405 |
|
| 2010 |
Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis. 13: 59-69. PMID 20221685 DOI: 10.1007/S10456-010-9164-2 |
0.3 |
|
| 2010 |
Wright TM, Rathmell WK. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. The Journal of Biological Chemistry. 285: 12916-24. PMID 20185829 DOI: 10.1074/Jbc.M109.073924 |
0.386 |
|
| 2010 |
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, ... Rathmell WK, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1502-7. PMID 20159822 DOI: 10.1200/Jco.2009.24.7759 |
0.351 |
|
| 2010 |
Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Current Opinion in Oncology. 22: 250-6. PMID 20154618 DOI: 10.1097/Cco.0B013E328337A5D2 |
0.406 |
|
| 2010 |
Rathmell WK, Pruthi R, Wallen E. Neoadjuvant treatment of renal cell carcinoma. Urologic Oncology. 28: 69-73. PMID 20123351 DOI: 10.1016/J.Urolonc.2009.02.001 |
0.376 |
|
| 2010 |
Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology. 75: 1108-13.e1. PMID 19931124 DOI: 10.1016/J.Urology.2009.06.105 |
0.371 |
|
| 2010 |
Brannon AR, Reddy A, Seiler M, Arreola A, Chen S, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, ... Rathmell WK, et al. Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns Cancer Research. 70: 1996-1996. DOI: 10.1158/1538-7445.Am10-1996 |
0.418 |
|
| 2009 |
Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports. 11: 94-101. PMID 19216840 DOI: 10.1007/S11912-009-0015-5 |
0.381 |
|
| 2008 |
Cowey CL, Rathmell WK. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opinion On Drug Discovery. 3: 311-327. PMID 20648240 DOI: 10.1517/17460441.3.3.311 |
0.449 |
|
| 2008 |
Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 14: 435-46. PMID 19061835 DOI: 10.1016/J.Ccr.2008.10.016 |
0.385 |
|
| 2008 |
Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. Plos One. 3: e3801. PMID 19030229 DOI: 10.1371/Journal.Pone.0003801 |
0.381 |
|
| 2008 |
Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 72: 864-8. PMID 18684493 DOI: 10.1016/J.Urology.2008.01.088 |
0.328 |
|
| 2008 |
Rathmell WK, Monk JP. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Urology. 72: 659-63. PMID 18649931 DOI: 10.1016/J.Urology.2008.05.009 |
0.365 |
|
| 2008 |
Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Review of Anticancer Therapy. 8: 63-73. PMID 18095884 DOI: 10.1586/14737140.8.1.63 |
0.423 |
|
| 2007 |
Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. The Journal of Clinical Investigation. 117: 3879-89. PMID 17992257 DOI: 10.1172/Jci32614 |
0.354 |
|
| 2007 |
Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3288-95. PMID 17664476 DOI: 10.1200/Jco.2007.10.8613 |
0.351 |
|
| 2007 |
Rathmell WK, Martz CA, Rini BI. Renal cell carcinoma. Current Opinion in Oncology. 19: 234-40. PMID 17414642 DOI: 10.1097/Cco.0B013E3280Ad4388 |
0.381 |
|
| 2007 |
Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 741s-746s. PMID 17255303 DOI: 10.1158/1078-0432.Ccr-06-2110 |
0.334 |
|
| 2005 |
Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Review of Anticancer Therapy. 5: 1031-40. PMID 16336094 DOI: 10.1586/14737140.5.6.1031 |
0.413 |
|
| 2004 |
Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Research. 64: 8595-603. PMID 15574766 DOI: 10.1158/0008-5472.Can-04-1430 |
0.461 |
|
| 2004 |
Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. American Journal of Clinical Oncology. 27: 109-12. PMID 15057147 DOI: 10.1097/01.Coc.0000046599.52805.00 |
0.334 |
|
| 2003 |
Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 3: 75-88. PMID 12559177 DOI: 10.1016/S1535-6108(02)00240-4 |
0.424 |
|
| 1998 |
Smider V, Rathmell WK, Brown G, Lewis S, Chu G. Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination. Molecular and Cellular Biology. 18: 6853-8. PMID 9774698 DOI: 10.1128/Mcb.18.11.6853 |
0.465 |
|
| 1997 |
Rathmell WK, Kaufmann WK, Hurt JC, Byrd LL, Chu G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Cancer Research. 57: 68-74. PMID 8988043 |
0.436 |
|
| 1996 |
Errami A, Smider V, Rathmell WK, He DM, Hendrickson EA, Zdzienicka MZ, Chu G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Molecular and Cellular Biology. 16: 1519-26. PMID 8657125 DOI: 10.1128/Mcb.16.4.1519 |
0.453 |
|
| 1994 |
Rathmell WK, Chu G. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Proceedings of the National Academy of Sciences of the United States of America. 91: 7623-7. PMID 8052631 DOI: 10.1073/Pnas.91.16.7623 |
0.444 |
|
| 1994 |
Smider V, Rathmell WK, Lieber MR, Chu G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science (New York, N.Y.). 266: 288-91. PMID 7939667 DOI: 10.1126/Science.7939667 |
0.436 |
|
| 1994 |
Rathmell WK, Chu G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Molecular and Cellular Biology. 14: 4741-8. PMID 7516471 DOI: 10.1128/Mcb.14.7.4741 |
0.438 |
|
| Show low-probability matches. |